-
Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows
Although the cost of antiretroviral treatment has fallen dramatically since generic manufacturers first began to manufacture versions of antiretroviral drugs in India in 2001, generic products have not been available in all countries due to patent restrictions.
- Categories
- Health Care, Investing
-
These Researchers Think They Have a Solution to the Global Crisis in Drug Prices
Jerome Zeldis remembers exactly how he felt when he heard about the $84,000 price tag on a powerful new hepatitis C treatment three years ago. “I was somewhere between annoyed and outraged,” recalled Zeldis, the former chief medical officer of the biotech juggernaut Celgene.
- Categories
- Health Care
-
South Africa’s Outdated Patent Laws Are Standing in the Way of Affordable, Lifesaving Drugs
The drug used to treat hepatitis B costs more than 10 times as much in South Africa as it does in India. Protests in Pretoria on Sept. 27 sought to highlight the exorbitant prices of many lifesaving drugs in the country. They lay the blame on medical patent laws that allow drug companies to charge full price for medication that can be purchased for much less in other parts of the world. The hepatitis B treatment, for instance, costs about $400 in South Africa, compared to just $35 in India.
-
Curing Hepatitis C, in an Experiment the Size of Egypt
Abdel Gawad Ellabbad knows exactly how he was infected with hepatitis C. As a schoolboy in this Nile Delta rice-farming village, his class marched to the local clinic every month for injections against schistosomiasis, a parasitic disease spread by water snails.
- Categories
- Health Care
- Region
- North Africa & Near East
The Best of NextBillion in Your Inbox Each Week!
Subscribe to NB Notes for news, jobs & on-the-ground insights from the world of emerging markets business.
We respect your privacy. Your information is safe and will never be shared.
Don't miss out. Subscribe today.